Jenny Filbey, the CEO of Mazen Animal Health, is a tenacious and driven leader who has devoted her career to bridging the gap between science and meaningful commercial ventures. Her expertise lies in assembling scientific knowledge, creating and funding start-ups, and navigating the intricacies of the life science industry. At Mazen, she has harnessed this experience to great effect.
Jenny’s vision extends beyond the ordinary. She is determined to revolutionize the animal vaccine market. To achieve this, she has assembled a world-class team and spearheaded the development and commercialization of Mazen’s groundbreaking oral biologics platform, Oralogix™. By providing a robust pipeline of products, this innovative platform aims to improve the lives of animals and those who care for them.
Jenny is deeply committed to a customer-centric approach, ensuring essential products reach the market to support producers’ needs. Additionally, she places significant emphasis on sustainable solutions in animal health, aiming to reduce animal losses and greenhouse gas emissions.
Previously, Jenny founded and led the biotech consultancy group, New Perspectives, where she focused her energy supporting life science clients in new company formation, leadership, business strategy, business development and licensing, operations and product commercialization. Jenny has over 25 years of experience in protein drug delivery in various roles at New Perspectives, Nektar, Nobex, and Hoescht where she was instrumental in advancing the application of cutting-edge technologies.
Dr. Filbey has a Ph.D. in Physical Chemistry from Virginia Tech and completed a post-doc at the C.N.R.S. (Centre National de la Recherche Scientifique) in Mulhouse, France.